| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Solana Company$1.82
+0.03 (+1.68%)
Market Cap
133.71 M
EPS
-109.67
P/E Ratio
-
Value Trade
869.58 K
SEC Financials
Q1 2026Dilution Risk
Revenue
3.62 M
Operating CF
-4.83 M
Total Assets
200.71 M
Total Liabilities
200.71 M
Equity
197.90 M
D/E Ratio
12,345
0.88 %
Week
9.57 %
1 Month
19.27 %
3 Month
-29.54 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
4.39 M
Monthly Burn
1.61 M
Runway
1.1 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
224.56 K
52 Week Range
1.59 - 205
% held by Insiders
29.24 %
% held by Institutions
25.09 %
Enterprise Value
129.31 M
Total Shares
54.89 M
Short %
3.06 %
Float Shares
54.89 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PoNS Breakthrough | gait and balance deficits in chronic stroke patients | — | 2025-09-25 | mean change treatment: 5.37 points; mean change control: 3.31 points; treatment group difference: 2.06; p value: 0.0233 Read More | Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Se Read More | |
PoNS Breakthrough | gait and balance deficits in chronic stroke patients | — | 2025-09-25 | mean change treatment: 5.37 points; mean change control: 3.31 points; treatment group difference: 2.06; p value: 0.0233 Read More | Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Se Read More | |
PoNS Breakthrough | gait and balance deficits in chronic stroke patients | — | 2025-09-25 | mean change treatment: 5.37 points; mean change control: 3.31 points; treatment group difference: 2.06; p value: 0.0233 Read More | Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Se Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HSDT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HSDT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HSDTSolana Company Partners with Alatau City to Advance Digital Asset Infrastructure and Blockchain Adoption in Central Asia
Solana Company has signed a Memorandum of Understanding with Alatau City to establish a blockchain partnership aimed at developing the city into a leading center for digital assets in Central Asia. The collaboration will focus on enhancing the digital asset ecosystem and integrating local institutions into global networks. This initiative is backed by a substantial investment of $6 billion.
Read more →HSDTSolana Unchained Phase 3 Closes Tonight: Last Chance to Enter Before Price Locks in for Phase 4
Solana Unchained is concluding Phase 3, offering a last chance to purchase tokens at $0.09 before the price increases to $0.12 in Phase 4. The project emphasizes a non-inflationary model supported by a fixed token supply and a unique fee structure that benefits the ecosystem. With a focus on security and operational integrity, the project aims to enhance its decentralized network.
Read more →HSDTSolana Company Board Unanimously Rejects Unsolicited Forward Industries Proposal
Solana Company (NASDAQ: HSDT) has rejected an unsolicited acquisition proposal from Forward Industries, deeming it to undervalue the company. The Board of Directors unanimously concluded that the proposal was not in the best interests of Solana and its stockholders. No further action is required from stockholders at this time.
Read more →HSDTSolana-Based Ecosystem Expands With New AI Utility Layer Targeting Real User Engagement
Solana Unchained is progressing in its public distribution phase, nearing the conclusion of Phase 3. The platform focuses on a utility layer integrating AI and decentralized finance, with a capped token supply to ensure market stability. Developers can leverage a comprehensive SDK for B2B integration, while governance models empower active participants in decision-making.
Read more →HSDTSolana Unchained Showcases Real-World Token Utility as New Generation of AI Crypto Projects Emerges
Solana Unchained has showcased its economic model, emphasizing the utility of its $UCHN token for machine learning services. With less than three days left in its Phase 1 public allocation, the project has seen increased participation. The platform integrates advanced AI tools and offers various tiers for user access, ensuring a capped token supply to prevent inflation.
Read more →HSDTSolana Company Reports First Quarter 2026 Financial Results NEWTOWN, Pa.
Solana Company (NASDAQ: HSDT) announced its financial results for the first quarter of 2026, reporting a revenue of $3.6 million, primarily from staking rewards. Despite this growth, the company faced a net loss of $99.8 million due to high operating expenses and significant unrealized losses on digital assets. Management emphasized their commitment to disciplined capital allocation and building recurring revenue streams, despite the challenges of the digital asset market. Overall, the results reflect both growth potential and substantial financial risks.
Read more →HSDTSolana Company to Release First Quarter 2026 Operating Results on May 15, 2026
Solana Company (NASDAQ: HSDT) announced it will release its first quarter operating results on May 15, 2026, after market close. The management will host a conference call to discuss these results and provide a business update. The webcast will be archived on the company's investor relations website for future access.
Read more →HSDTJito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific Region
The Jito Foundation has partnered with Solana Company (NASDAQ: HSDT) to enhance institutional blockchain infrastructure across the Asia-Pacific region. This collaboration will focus on deploying high-performance Solana validators and developing advanced staking solutions tailored for institutional investors. The partnership aims to facilitate institutional adoption of Solana's ecosystem in key financial hubs.
Read more →HSDTSolana Company (NASDAQ: HSDT) Announces Registered Direct Offering of Common Stock to Global Institutional Investor
Solana Company (NASDAQ: HSDT) has announced a registered direct offering of 3,076,922 shares of Class A common stock at $2.60 per share, aiming to raise approximately $8 million. The offering is led by Mirae Asset and will fund the company's digital asset treasury and other strategic initiatives. The company has also entered a put option agreement with investors, allowing for future repurchase under specific conditions.
Read more →HSDTSOLANA COMPANY - HSDT Solana Company (NASDAQ: HSDT) Announces Registered Direct Offering of Common Stock to Global Institutional Investor Newtown, PA
Solana Company (NASDAQ: HSDT) announced a registered direct offering of 3,076,922 shares of Class A common stock at a price of $2.60 per share to a global institutional investor, Mirae Asset. The offering is expected to generate approximately $8 million in proceeds, which will be utilized for acquiring Solana tokens, working capital, and business expansion. The transaction aims to leverage opportunities in the digital asset market and optimize shareholder value. The company has partnered with Hashkey Capital to facilitate the offering.
Read more →HSDTSolana Company (NASDAQ: HSDT) Appoints Madelene Gani as Chief Operating Officer and Deputy CFO to Lead Next Phase of Growth
Solana Company has appointed Madelene Gani as Chief Operating Officer and Deputy CFO, effective April 6, 2026. Gani brings over 25 years of experience in finance and operations, having previously held leadership roles at companies like Hedera Hashgraph and Gemini. Her expertise is expected to drive Solana's growth and enhance its operational capabilities as the company prepares for its next phase.
Read more →HSDTSOLANA COMPANY - HSDT Solana Company (NASDAQ: HSDT) Appoints Madelene Gani as Chief Operating Officer and Deputy CFO to Lead Next Phase of Growth A veteran architect of Gemini's Asia Pacific expansi
Solana Company (NASDAQ: HSDT) has appointed Madelene Gani as Chief Operating Officer and Deputy CFO to guide its next growth phase. Gani, a seasoned finance executive with a background at major crypto and fintech firms, is expected to instill operational excellence and diversify revenue. Her experience includes significant roles at Hedera Hashgraph and Gemini, where she successfully led important transformations. This appointment comes as Solana Company transitions toward active business development and aims to capitalize on opportunities within the digital asset ecosystem.
Read more →HSDTSolana Company Reports Fourth Quarter and Full Year 2025 Financial Results
Solana Company (HSDT) reported its financial results for Q4 and full year 2025, highlighting $5.1 million in staking rewards and a net income of $325.6 million for Q4. Despite these gains, the company faced significant operational losses and challenges due to adverse market conditions in the cryptocurrency sector. The firm remains committed to its digital asset treasury strategy and long-term growth objectives.
Read more →HSDTSolana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026
Solana Company (NASDAQ: HSDT) is set to release its fourth quarter and full year operating results on March 30, 2026, after market close. The company, known for its neurotech innovations, will also host a conference call to discuss these results and provide further business updates. This marks an important event for stakeholders and investors.
Read more →HSDTSolana Company (NASDAQ: HSDT) Announces Plan for the Pacific Backbone, a High-Speed Infrastructure Buildout for Solana
Solana Company (NASDAQ: HSDT) has announced a strategic roadmap for building a low-latency infrastructure in the Asia Pacific region, aimed at enhancing staking and validation for its ecosystem. The project will connect major cities like Seoul, Tokyo, Singapore, and Hong Kong, with plans to launch new liquidity products within 12 to 18 months. The initiative is expected to support existing developers and attract new financial institutions and tech companies to the Solana network.
Read more →HSDTSolana Company (NASDAQ: HSDT) Becomes First Digital Asset Treasury to Enable Borrowing Against Natively Staked SOL in Qualified Custody
Solana Company (HSDT) has launched the first digital asset treasury allowing borrowing against natively staked SOL through a tri-party custody model. This collaboration with Anchorage Digital and Kamino aims to attract institutional capital to Solana's DeFi ecosystem. The model enables institutions to earn staking rewards while maintaining compliance and operational control. It is designed to serve as a scalable blueprint for future institutional treasury operations.
Read more →HSDTSolana Company Reports Third Quarter 2025 Financial Results NEWTOWN, Pa.
Solana Company (NASDAQ: HSDT) reported its financial results for the third quarter of 2025, revealing a significant net loss of $352.8 million. Despite a growing focus on digital assets and a recent PIPE transaction, the company faced increased operational expenses totaling $36 million. The reported revenue for the quarter was $697,000, which included new staking rewards income. Future growth will rely on effective execution of their digital treasury strategy, amidst ongoing financial challenges.
Read more →HSDTx 2 Disclaimer This presentation has been prepared by Solana Company (the “Company”) solely for information purposes. The information contained in this presentation has been prepared solely to assist intere
The Solana Company (ticker: HSDT) is facing potential regulatory challenges that may classify its SOL holdings as securities under the Investment Company Act of 1940. This change could adversely impact the market price of SOL and the company's overall financial status. Additionally, risks such as security breaches and market volatility associated with SOL assets pose significant threats to the company's operations. The inability to effectively manage SOL strategy may further affect HSDT's stock price and financial obligations.
Read more →HSDTSolana Company Announces Updated SOL Holdings and Industry Leading Staking Yield NEWTOWN, Pa.
Solana Company (HSDT) has announced an update on its SOL holdings and staking performance, revealing that it now holds over 2.3 million SOL and has a cash reserve exceeding $15 million. The company achieved an average gross staking yield of 7.03% APY in October, which surpasses the average of top 10 validators. Executive statements highlight a focus on transparency and growth within the Solana ecosystem, emphasizing the company's disciplined capital strategy. Overall, the results suggest strong engagement and performance in the rapidly growing blockchain market.
Read more →HSDTSolana Company Executive Chairman's Message: October 20th, 2025 NEWTOWN, Pa.
Solana Company Executive Chairman released a message outlining the company's strategy to move forward with the resale registration of shares from a recent private placement. The company positions itself as a significant player in the Solana digital asset treasury market, inviting institutional investors to engage. By navigating market volatility and establishing a strong capital base, HSDT aims to maximize shareholder value and operate similar to Berkshire Hathaway within the Solana ecosystem. Challenges related to market performance and execution risks remain, but the company's leadership is optimistic about long-term success.
Read more →HSDTPreeminent SOL Treasury Company Helius (NASDAQ:HSDT) Announces Corporate Name Change to Solana Company and Letter of Intent with Solana Foundation HSDT Solana Company's Mission is to maximize SOL per share on one of the
Helius Medical Technologies, Inc. has officially changed its name to Solana Company, signifying a renewed focus on the Solana blockchain and its potential for commercial applications. The move is accompanied by a letter of intent with the Solana Foundation, establishing a commitment to on-chain activities exclusively on Solana and promoting joint initiatives. The company's strategy includes accumulating Solana's native digital asset, SOL, to enhance its treasury while leveraging its past financing. This shift underscores Solana Company's aim to become a leading entity within the burgeoning blockchain sector.
Read more →HSDTCautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Se
Helius Medical Technologies announced its submission of a 510(k) application to the FDA for the PoNS device to expand its label for treating gait and balance deficits in chronic stroke patients. This submission is backed by positive data from their Stroke Registrational Program, which indicates that PoNS therapy is more effective than traditional physical therapy alone. The results showed statistically significant improvements in gait assessment scores, suggesting the therapy's potential benefits for stroke rehabilitation. This step aligns with Helius' ongoing commitment to enhancing treatment options for neurologic conditions.
Read more →HSDTHelius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain Newtown, Pa.
Helius Medical Technologies, Inc. (HSDT) has initiated its asset acquisition strategy by purchasing over 760,190 SOL tokens, aligning with its Solana treasury strategy. The company holds over $335 million in cash and aims to use these funds for further acquisitions. Executives expressed commitment to maximizing shareholder value and highlighted the potential productivity of SOL within the Solana ecosystem. However, they also acknowledged uncertainties and risks related to the evolving market conditions and regulatory environment.
Read more →HSDTHelius (NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital Closes Over $500 Million Private Placement to Launch SOL Treasury Company Preeminent SOL-backed treasury vehicle - with potential to raise over
Helius Medical Technologies, Inc. has successfully closed a private placement offering, generating over $500 million with additional potential of $750 million from stapled warrants. This funding aims to launch the SOL Treasury Company, positioning Solana's cryptocurrency as the primary treasury reserve asset. The company emphasizes the growth potential of Solana in decentralized finance, facilitated by notable partnerships. Leadership appointments from experienced figures in investment banking and cryptocurrency sectors underscore a strategic push for the digital asset treasury model.
Read more →HSDTHelius (NASDAQ:HSDT) , in Partnership with Pantera Capital and Summer Capital Announces Over $500 Million in Funding to Launch SOL Treasury Company Preeminent SOL-backed treasury vehicle - with potential to deliver over
Helius Medical Technologies (NASDAQ:HSDT) announced a successful funding round of over $500 million in partnership with Pantera Capital and Summer Capital. This funding will support the launch of the SOL Treasury Company, designed to utilize the SOL cryptocurrency as a treasury asset. With a focus on accelerating Solana's growth, the company plans to implement a digital asset treasury strategy, positioning itself to leverage the benefits of Solana's blockchain capabilities. The offering is set to close around September 18, 2025, pending customary conditions.
Read more →HSDTHelius Medical Technologies, Inc. Unaudited Condensed Interim Consolidated Balance Sheet The unaudited balance sheet has been filed in order to show compliance with the Nasdaq requirement that the Company maintain a mini
Helius Medical Technologies, Inc. filed an unaudited condensed interim consolidated balance sheet to comply with Nasdaq's requirement for a minimum stockholders' equity of $2.5 million. As of June 17, 2025, the balance sheet demonstrates total assets of $8,246,000 against total liabilities of $1,685,000, indicating a positive current assets to liabilities ratio. However, the report was not audited or reviewed by the independent accounting firm, and there is a notable accumulated deficit.
Read more →HSDTHelius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria --Company previously granted extension until
Helius Medical Technologies, Inc. has announced that it has complied with Nasdaq's minimum bid price requirement as of June 3, 2025. The company has been granted an extension until June 30, 2025, to meet additional equity requirements. The Nasdaq Listing Qualifications hearing process will remain open until Helius demonstrates compliance with all listing requirements. Helius is recognized for its innovative approach to neuromodulation aimed at improving lives impacted by neurologic diseases.
Read more →HSDTHelius Medical Technologies Announces Reverse Stock Split NEWTOWN, Pa.
Helius Medical Technologies, Inc. announced a reverse stock split of its Class A common stock at a ratio of 1-for-15, effective May 1, 2025. This decision follows the approval from stockholders and aims to comply with Nasdaq listing requirements. The reverse split will reduce the number of outstanding shares from approximately 7.9 million to around 0.5 million. The Company's trading symbol on Nasdaq will remain 'HSDT'.
Read more →HSDTHelius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market NEWTOWN, Pa.
Helius Medical Technologies, Inc. announced the exercise of existing warrants and issuance of new warrants in a private placement, generating approximately $3.7 million in gross proceeds. The existing warrants, exercisable for nearly 5 million shares, have been exercised at a reduced price, allowing the company to strengthen its capital position. The new warrants will require stockholder approval before becoming fully exercisable. Helius continues to focus on its Portable Neuromodulation Stimulator (PoNS) device, aimed at addressing neurological deficits.
Read more →HSDTHelius Announces First Portable Neuromodulation Stimulator (PoNS ) System Sale to the Veterans Affairs (VA) Healthcare System Initial order placed with Company's distributor at contracted price and represents operational
Helius Medical Technologies has announced the sale of its first Portable Neuromodulation Stimulator (PoNS) System to the Veterans Affairs (VA) Healthcare System, marking a significant operational step for the company. The initial sale, facilitated through Lovell Government Services, positions Helius to penetrate a patient population of up to 70,000 veterans suffering from multiple sclerosis. This order not only demonstrates market demand but also aids in efforts for broader Medicare reimbursement discussions. The integration into the VA system represents Helius's commitment to supporting veterans with gait deficits due to MS.
Read more →HSDTHelius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives NEWTOWN, Pa.
Helius Medical Technologies, Inc. has announced the initiation of a process to explore various strategic alternatives aimed at maximizing stockholder value. The company faces challenges due to a deferral of reimbursement payment determinations for its PoNS Controller and suboptimal pricing for the PoNS Mouthpiece, which limits operational advancements. Helius has engaged B. Riley Securities as a financial advisor for this review process. Updates on this strategic exploration are not expected until the Board of Directors determines that disclosure is appropriate or required.
Read more →HSDTHelius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results -- Company to host call at 4:30pm today -- NEWTOWN, Pa.
Helius Medical Technologies, Inc. reported its second quarter 2024 financial results, revealing a total revenue of $182,000, which is a decrease from the previous year's $256,000. The company announced a significant achievement with the first third-party reimbursement for its PoNS therapy, and expects vital developments in the upcoming third quarter, including results from clinical studies. Helius is also actively working on a Canadian study to bolster its FDA submission and aims to enhance national reimbursement efforts.
Read more →HSDTHelius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results -- Company to host call at 4:30pm today -- NEWTOWN, Pa.
Helius Medical Technologies, Inc. has reported its financial results for the first quarter of 2024, showing a revenue increase to $135,000 compared to $111,000 in the same quarter in 2023. The company achieved a significant milestone with the release of preliminary Medicare payment determinations for its PoNS therapy. Operating expenses decreased, contributing to an improved operating loss of $3.4 million, lower than the previous year's loss. Helius also raised $5.6 million in a public offering to support its operations through 2025.
Read more →HSDTHelius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS ) -- The Centers for Medicare & Medicaid Services (CMS) released its prelim
Helius Medical Technologies, Inc. announced a preliminary Medicare payment determination for its Portable Neuromodulation Stimulator (PoNS) device by the Centers for Medicare & Medicaid Services (CMS). Proposed payment rates were outlined for both the PoNS Controller and Mouthpiece, with the company emphasizing their intent to argue for higher reimbursement at an upcoming public meeting. This development is seen as a positive step, potentially allowing for greater reimbursement from third-party payers and improving cash flow. However, the company acknowledged uncertainties regarding the final adoption of these rates.
Read more →HSDTHelius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering NEWTOWN, Pa.
Helius Medical Technologies, Inc. announced a public offering priced at $6.4 million, involving 804,999 shares of Class A common stock and pre-funded warrants. The company plans to utilize the proceeds for funding operations and general corporate purposes. The offering is expected to close on or about May 9, 2024, subject to customary conditions. The securities are being offered under an effective registration statement registered with the SEC.
Read more →HSDTHelius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results -- Company to host call at 4:30pm today - NEWTOWN, Pa.
Helius Medical Technologies, Inc. announced its fourth quarter and full year 2023 financial results, including a decrease in total revenue and improvements in net loss. The company highlighted the assignment of HCPCS codes for its PoNS device, which facilitates Medicare reimbursement efforts. Helius is targeting a regulatory submission for U.S. authorization of the PoNS therapy by early 2025 and continues to engage with CMS regarding coverage. Despite financial challenges, the company has raised $1.3 million under its ATM program, extending its cash runway into the third quarter of 2024.
Read more →HSDTHelius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS ) Mouthpiece and Controller -- Significant step toward reimbursement for the only medical device approved in the U.S. fo
Helius Medical Technologies, Inc. announced that the Centers for Medicare & Medicaid Services has assigned HCPCS codes for its Portable Neuromodulation Stimulator (PoNS) mouthpiece and controller, marking a significant advance toward reimbursement for the device. This achievement allows the company to negotiate reimbursement with third-party payers, with expectations for a reimbursement determination to be made by October 1, 2024. Additionally, the company recently extended its cash runway into the third quarter of 2024 through stock issuances. PoNS is indicated for treating gait deficits due to multiple sclerosis, and its future potential includes seeking marketing authorization for stroke treatment in the U.S.
Read more →HSDTEmpowering Neuroplasticity PoNS TherapyTM for Balance and Gait Deficits in Patients with Neurological Disorders December 2023 NASDAQ:HSDT Legal Disclaimers This presentation contains forward-looking statements, including
Helius Medical Technologies has highlighted the positive impact of its PoNS Therapy in improving balance and gait deficits in patients with neurological disorders, particularly multiple sclerosis. Recent studies have shown that patients who used the PoNS device experienced significant improvements in their functional gait assessment. The device, which stimulates the tongue, induces neuroplasticity, suggesting potential broad applications in rehabilitation therapies for neurological conditions. Helius continues to gather real-world evidence to reinforce the credibility of its therapy's benefits.
Read more →HSDTHelius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results -- Cash runway extended into Q2 2024 -- -- Company to host call at 4:30pm today - NEWTOWN, Pa.
Helius Medical Technologies, Inc. has reported its third quarter 2023 financial results, highlighting a cash runway that extends into Q2 2024. The company has made significant progress, including establishing new reimbursement avenues for its PoNS system in both the U.S. and Canada. Despite experiencing a decrease in total revenue and an increased net loss compared to the previous year, the company remains optimistic about the therapeutic benefits of its PoNS Therapy and its positive effect on patient outcomes. Helius plans to host a conference call to discuss these results further.
Read more →HSDTHelius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on
Helius Medical Technologies, Inc. announced the release of its third quarter 2023 financial results, scheduled for November 9, 2023. The company anticipates revenues in the range of $140 - $150 thousand, which indicates a decline due to the conclusion of the Patient Therapy Access Program. Helius notes it will maintain approximately $7 million in cash, extending its runway into Q2 2024. A conference call will follow the release, offering further business updates and plans regarding their commercialization strategy for the PoNS device.
Read more →HSDTHelius Medical Technologies, Inc. Receives UPC Numbers for its PoNS System and Mouthpiece -- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology -- -- PoNS system and mouthpiece will be
Helius Medical Technologies, Inc. has received UPC numbers for its Portable Neuromodulation Stimulator (PoNS) system and mouthpiece, assigned by Wolters Kluwer Health. This inclusion in a pharmacy database utilized by 17 out of 20 top-grossing pharmacy benefit managers will enhance Helius' ability to secure reimbursement. The UPC codes will allow Helius to streamline negotiations with third-party payers. PoNS is expected to be one of the few products with both pharmacy and device codes, which provides distinct pathways for potential reimbursement.
Read more →HSDTHelius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria NEWTOWN, Pa.
Helius Medical Technologies, Inc. announced compliance with all Nasdaq listing criteria as of August 31, 2023. The company satisfied the minimum bid price requirement and all other requirements for continued listing on The Nasdaq Capital Market. This development marks a positive milestone for Helius, as it enhances its operational stability while focusing on its innovative therapeutic approaches for neurologic deficits.
Read more →HSDTHelius Medical Technologies, Inc. Reports Second Quarter 2023 Financial Results -- Total Q2 revenue up 115% over prior year; 131% over Q1 2023 -- -- Company to host call at 4:30pm today -- NEWTOWN, Pa.
Helius Medical Technologies, Inc. reported a significant increase in revenue for Q2 2023, rising 115% from the previous year and 131% from Q1 2023. The company attributed this growth to the early purchase of its PoNS therapy device before the expiration of the PTAP program. Despite the positive revenue trends, the company anticipates a decrease in U.S. sales in the latter half of the year. Helius continues to focus on securing reimbursement and expanding its product availability as part of its growth strategy.
Read more →HSDTHelius Medical Technologies, Inc. Reports First Quarter 2023 Financial Results -- Company to host call at 4:30pm today -- NEWTOWN, Pa.
Helius Medical Technologies, Inc. reported its first quarter 2023 financial results, highlighting a revenue of $111 thousand, down from $190 thousand in the same period last year. The company continues to focus on its e-commerce transition and commercial rollout of its PoNS therapy. Despite a decline in revenue primarily due to lower Canadian sales, Helius remains optimistic about growth in the U.S. market and is implementing strategies to improve accessibility to its products. The company reported a net loss of $2.5 million for the quarter, a decrease from the previous year's loss of $4.3 million.
Read more →HSDTHelius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary NEWTOWN, Pa.
Helius Medical Technologies, Inc. declared a dividend of Series B Preferred Stock aimed at Class A common stockholders to facilitate a potential reverse stock split. Each share of Series B Preferred Stock will allow for significant voting power on key proposals concerning the company’s capital structure. Additionally, the company underscores the strategic importance of this move amidst ongoing challenges in achieving their business objectives and regulatory approvals.
Read more →HSDTHelius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results -- Full year 2022 revenue of $0.8 million, an increase of 51% over 2021 -- -- Year-end cash balance of $14.5 million -- -- Com
Helius Medical Technologies, Inc. reported a significant revenue increase of 51% in 2022, reaching $0.8 million, along with a year-end cash balance of $14.5 million. The company has experienced strong growth and plans to expand access to its PoNS Therapy for patients with balance and gait deficits. Despite challenges, including a rising net loss for the fourth quarter, Helius is optimistic about its future momentum and additional market opportunities following recent product authorizations. The company anticipates positive revenue trends in 2023, contingent on effective commercial rollout and reimbursement strategies.
Read more →HSDTHelius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022 -- Q4 2022 revenue projected to range from $275,000 to $285,000 -- -- Full year 2022 revenue projected to range fr
Helius Medical Technologies, Inc. announced preliminary unaudited results for Q4 and full-year 2022, projecting revenues of $275,000 to $285,000 for Q4 and $780,000 to $790,000 for the full year. The company's performance was positively impacted by the U.S. commercial launch of PoNS Therapy, which aims to improve balance and gait for patients. Helius also reported a cash balance of $14.5 million at year-end, and plans to provide a detailed operational update during its upcoming earnings call in March. However, the company cautioned that preliminary figures are estimates and actual results could vary significantly.
Read more →HSDTHelius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results -- Total Q3 revenue up 80% over prior year -- -- Cash on hand expected to fund operations through 2023 -- -- Company to host call at 8:30am t
Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results -- Total Q3 revenue up 80% over prior year -- -- Cash on hand expected to fund operations through 2023 -- -- Company to host call at 8:30am today - NEWTOWN, Pa., November 14, 2022 (GLOBE NEWSWIRE)
Read more →HSDTHelius Medical Technologies, Inc. Reports Second Quarter 2022 Financial Results -- Net proceeds from August 2022 financing and cash on hand expected to fund operations through 2023 - -- Company to host call at 4:30pm tod
Helius Medical Technologies, Inc. Reports Second Quarter 2022 Financial Results -- Net proceeds from August 2022 financing and cash on hand expected to fund operations -- Company to host call at 4:30pm today -- NEWTOWN, Pa., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Helius Medical Tec
Read more →HSDTHelius Medical Technologies, Inc. Announces Pricing of $18 Million Public Offering NEWTOWN, Pa.
Helius Medical Technologies, Inc. Announces Pricing of $18 Million Public Offering August 5, 2022 - Helius Medical Technologies, Inc. (Nasdaq: HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the pricing of a public offer
Read more →HSDTHelius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS -- Company to host call at 9:00am today with CEO, CFO, CMO and VP Sales & Marketing --
Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS -- Company to host call at 9:00am today with CEO, CFO, CMO and VP Sales & Marketing -- NEWTOWN, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Helius Medi
Read more →HSDTHelius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS -- First patients have purchased PoNS devices to initiate PoNS Therapy -- -- Nineteen PoNS device prescriptions have been written in the U.S. s
Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS -- First patients have purchased PoNS devices to initiate PoNS Therapy -- -- Nineteen PoNS device prescriptions have been written in the U.S. since recent commercial launch -- NEWTOWN, Pa., April 27,
Read more →HSDTLegal Disclaimers This presentation contains forward-looking statements, including statements regarding the Company's future strategic and operational execution, the next phase of the Company's market development activit
Empowering Neuroplasticity PoNS Therapy for Balance and Gait Deficits in Patients with Neurological Disorders Legal Disclaimers This presentation contains forward-looking statements, including statements regarding the Company's future strategic and operational execution, the ne
Read more →HSDTHelius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results NEWTOWN, Pa., March 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today
Read more →HSDTHelius Medical Technologies, Inc. Provides Corporate Update -- Fourth Quarter 2021 Revenue Projected to Range from $250,000 to $260,000 -- -- Unaudited Year End Cash Balance of $11 million -- -- Continued Progress Toward
Helius Medical Technologies, Inc. Provides Corporate Update -- Fourth Quarter 2021 Revenue Projected to Range from $250,000 to $260,000 -- -- Unaudited Year End Cash Balance of $11 million -- -- Continued Progress Toward U.S. Commercial Launch of PoNS for Multiple Sclerosis --
Read more →HSDTHelius Medical Technologies, Inc. Reports Third Quarter 2021 Financial Results NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Third Quarter 2021 Financial Results NEWTOWN, Pa., November 10, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today reported fi
Read more →HSDTHelius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock NEWTOWN, Pa.
Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock NEWTOWN, Pa., November 9, 2021 - Helius Medical Technologies, Inc. (Nasdaq: HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced
Read more →HSDTHelius Medical Technologies, Inc. Receives PoNS Market Authorization in Australia NEWTOWN, Pa.
Helius Medical Technologies, Inc. Receives PoNS Market Authorization in Australia NEWTOWN, Pa., November 4, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced it
Read more →HSDTHelius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors NEWTOWN, Pa.
Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors NEWTOWN, Pa., September 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announc
Read more →HSDTHelius Medical Technologies, Inc. Announces Voluntary De-Listing from Toronto Stock Exchange NEWTOWN, Pa.
Helius Medical Technologies, Inc. Announces Voluntary De-Listing from Toronto Stock Exchange NEWTOWN, Pa., August 25, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological welln
Read more →HSDTHelius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke NEWTOWN, Pa.
Helius Medical Technologies, Inc. Announces FDA Breakthrough Device Designation for the Treatment of Dynamic Gait and Balance Deficits Following a Stroke NEWTOWN, Pa., August 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the
Read more →HSDTHelius Medical Technologies, Inc. Reports Second Quarter 2021 Financial Results NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Second Quarter 2021 Financial Results NEWTOWN, Pa., August 12, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today re
Read more →HSDTHelius Medical Technologies, Inc. Expands Executive Leadership Team with the Appointment of Dane C. Andreeff as President and Chief Executive Officer and Jeffrey S. Mathiesen as Chief Financial Officer NEWTOWN, Pa.
Helius Medical Technologies, Inc. Expands Executive Leadership Team with the Appointment of Dane C. Andreeff as President and Chief Executive Officer and Jeffrey S. Mathiesen as Chief Financial Officer NEWTOWN, Pa., June 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies
Read more →HSDTHelius Medical Technologies, Inc. Reports First Quarter 2021 Financial Results NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports First Quarter 2021 Financial Results NEWTOWN, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today report
Read more →HSDTHelius Medical, Inc Receives U.S. Marketing Authorization for the PoNS Device First and only tongue-delivered neuromodulation therapy provides new treatment option for U.S. patients living with gait deficit due to sympto
Helius Medical, Inc Receives U.S. Marketing Authorization for the PoNS Device First and only tongue-delivered neuromodulation therapy provides new treatment option for U.S. patients living with gait deficit due to symptoms from multiple sclerosis NEWTOWN, Pa., March 29, 2021 (G
Read more →HSDTHelius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results NEWTOWN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological welln
Read more →HSDTHelius Medical Technologies, Inc. Announces Pricing of $9.6 Million Underwritten Public Offering Priced At Market NEWTOWN, Pa.
Helius Medical Technologies, Inc. Announces Pricing of $9.6 Million Underwritten Public Offering Priced At Market NEWTOWN, Pa., January 28, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused
Read more →HSDTHelius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards The Company's Stock Will Continue to be Listed and Trade on The Nasdaq Stock Market NEWTOWN, Pa.
Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards The Company's Stock Will Continue to be Listed and Trade on The Nasdaq Stock Market NEWTOWN, Pa., January 19, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("
Read more →HSDTHelius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis Submits formal
Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis Submits formal response to the U.S. Food and Drug Administration's request
Read more →HSDTHelius Medical Technologies, Inc. Announces Reverse Stock Split NEWTOWN, Pa.
Helius Medical Technologies, Inc. Announces Reverse Stock Split NEWTOWN, Pa., December 31, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, announced today a 1-fo
Read more →HSDTHelius Medical Technologies, Inc. Reports Third Quarter of Fiscal Year 2020 Financial Results NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Third Quarter of Fiscal Year 2020 Financial Results NEWTOWN, Pa., November 12, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological we
Read more →HSDTHelius Medical Technologies Announces Closing of $3.4 Million Private Placement NEWTOWN, Pa.
Helius Medical Technologies Announces Closing of $3.4 Million Private Placement NEWTOWN, Pa., October 26, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, announc
Read more →HSDTHelius Medical Technologies Announces $3.4 Million Private Placement NEWTOWN, Pa.
Helius Medical Technologies Announces $3.4 Million Private Placement NEWTOWN, Pa., October 21, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, announced today th
Read more →HSDTHelius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and Clearance of the PoNS Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis NEWTOWN
Helius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and Clearance of the PoNS Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis NEWTOWN, Pa., October 19, 2020 (GLOBE NEWSWIRE) -- Helius Medical
Read more →HSDTThe Last Frontier in Healthcare Empowering the Natural Healing Process of the Brain September 2020 Legal Disclaimers This presentation contains forward-looking statements, including statements about: uncertainties regard
Legal Disclaimers This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process, whether the results of our clinical trials will be sufficient to support an FDA, CE Mark or TGA approval of the PoNS d
Read more →HSDTHelius Medical Technologies, Inc. Announces Departure of President, Chief Executive Officer and Chairman Philippe Deschamps; Board of Directors Appoints Dane C. Andreeff as Interim President and Chief Executive Officer a
Helius Medical Technologies, Inc. Announces Departure of President, Chief Executive Officer and Chairman Philippe Deschamps; Board of Directors Appoints Dane C. Andreeff as Interim President and Chief Executive Officer and Appoints Blane Walter as Chairman of the Board of Directo
Read more →HSDTHelius Medical Technologies, Inc. Reports Second Quarter of Fiscal Year 2020 Financial Results NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Second Quarter of Fiscal Year 2020 Financial Results NEWTOWN, Pa., August 12, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wel
Read more →HSDTHelius Medical Technologies, Inc. Submits Request for FDA Clearance for PoNS TM Device; Reports Preliminary Financial Results for the Second Quarter and Six Months Ended
Helius Medical Technologies, Inc. Submits Request for FDA Clearance for PoNSTM Device; Reports Preliminary Financial Results for the Second Quarter and Six Months Ended June 30, 2020 NEWTOWN, PA, | August 6, 2020 - Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Heli
Read more →HSDTHelius Medical Technologies, Announces the Dismissal of the Shareholder Class Action Lawsuit NEWTOWN, Pa. |
Helius Medical Technologies, Announces the Dismissal of the Shareholder Class Action Lawsuit NEWTOWN, Pa. | July 14, 2020 Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ( Helius or the Company ), announced the dismissal of a putative shareholder class action in the S
Read more →HSDTHelius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis NEWTOWN, Pa. |
Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis NEWTOWN, Pa. | May 12, 2020 - Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ( Helius
Read more →HSDTHelius Medical Technologies, Inc. Reports First Quarter of Full Year 2020 Financial Results; Updates Full Year 2020 Outlook NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports First Quarter of Full Year 2020 Financial Results; Updates Full Year 2020 Outlook NEWTOWN, Pa., May 7, 2020 (GLOBE NEWSWIRE) Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ( Helius or the Company ), a neurotech company focus
Read more →HSDTHelius Medical Technologies, Inc. Announces Publication of its PoNS Registrational Clinical Trial (TBI-001) in TBI 122 Subject, Multicenter, Double-Blind, Randomized, Clinical Trial Finds PoNS Treatment TM found Signific
Helius Medical Technologies, Inc. Announces Publication of its PoNS Registrational Clinical Trial (TBI-001) in TBI 122 Subject, Multicenter, Double-Blind, Randomized, Clinical Trial Finds PoNS TreatmentTM found Significant Improvement in Balance and Gait Deficits for Individual
Read more →HSDTHelius Medical Technologies Appoints Jeffrey S. Mathiesen to its Board of Directors NEWTOWN, Pa. |
Helius Medical Technologies Appoints Jeffrey S. Mathiesen to its Board of Directors NEWTOWN, Pa. | April 22, 2020 Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) ( Helius or the Company ), a neurotech company focused on neurological wellness, today announced the app
Read more →HSDTLegal Disclaimers www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process, including wh
A Revolution in Mind March 2020 Exhibit 99.1 Legal Disclaimers www.heliusmedical.com | Nasdaq:HSDT | TSX:HSM This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process, including whether the resu
Read more →HSDTHelius Medical Technologies Announces $2.2 Million Registered Direct Offering NEWTOWN, Pa. |
Helius Medical Technologies Announces $2.2 Million Registered Direct Offering NEWTOWN, Pa. | March 18, 2020 - Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, announced today that it has
Read more →HSDTHelius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results; Introduces Full Year 2020 Outlook NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results; Introduces Full Year 2020 Outlook NEWTOWN, Pa., March 12, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech co
Read more →HSDTHelius Medical Technologies Reports Preliminary Unaudited Fourth Quarter and Full Year Unaudited 2019 Financial Results, Provides Commercial and Regulatory Update and Announces Submission to Health Canada for Multiple Sc
Helius Medical Technologies Reports Preliminary Unaudited Fourth Quarter and Full Year Unaudited 2019 Financial Results, Provides Commercial and Regulatory Update and Announces Submission to Health Canada for Multiple Sclerosis (MS) Label Expansion and New US Regulatory Prioritiz
Read more →HSDTHelius Medical Technologies, Inc. Announces Proposed Public Offering NEWTOWN, Pa.
Helius Medical Technologies, Inc. Announces Proposed Public Offering NEWTOWN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ( Helius or the Company ), a neurotech company focused on neurological wellness, announced today that it h
Read more →HSDTHelius Medical Technologies, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update; Updates Full Year 2019 Outlook NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update; Updates Full Year 2019 Outlook NEWTOWN, Pa., November 12, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"),
Read more →HSDTHelius Medical Technologies, Inc. Announces Update on US Regulatory Strategy Following Pre-Submission Meeting with
Helius Medical Technologies, Inc. Announces Update on US Regulatory Strategy Following Pre-Submission Meeting with FDA NEWTOWN, PA., October 24, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company fo
Read more →HSDTHelius Medical Technologies, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update; Reaffirms Full Year 2019 Outlook NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update; Reaffirms Full Year 2019 Outlook NEWTOWN, Pa., August 8, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"),
Read more →HSDTHelius Medical Technologies, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update; Reaffirms Full Year 2019 Outlook NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update; Reaffirms Full Year 2019 Outlook NEWTOWN, Pa., May 9, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a ne
Read more →HSDTHelius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS Device NEWTOWN, PA.
Helius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS Device NEWTOWN, PA., April 10, 2019 - (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Com
Read more →HSDTLegal Disclaimers This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process, including whether the results of our clinical trials will
A Revolution in Mind March 2019 184 60 36 238 116 33 109 110 114 146 161 153 Exhibit 99.1 Legal Disclaimers This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process, including whether the resul
Read more →HSDTExhit Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Introduces Full Year 2019 Outlook NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Introduces Full Year 2019 Outlook NEWTOWN, Pa., March 14, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech
Read more →HSDTHelius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS Device NEWTOWN, Pa.
Helius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS Device NEWTOWN, Pa., January 25, 2019 - (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "C
Read more →HSDTHelius Medical Technologies, Inc. Submits CE Mark Application for PoNS Device NEWTOWN, Pa.
Helius Medical Technologies, Inc. Submits CE Mark Application for PoNS Device NEWTOWN, Pa., December 12, 2018 - (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today
Read more →HSDTHelius Medical Technologies, Inc. Announces Proposed Public Offering of Class A Common Stock NEWTOWN, Pa.
Helius Medical Technologies, Inc. Announces Proposed Public Offering of Class A Common Stock NEWTOWN, Pa., November 14, 2018 (GLOBE NEWSWIRE) Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ( Helius or the Company ) announced today that it intends to offer and sell, s
Read more →HSDTHelius Medical Technologies, Inc. Reports Third Quarter 2018 Financial Results NEWTOWN, Pa.
Helius Medical Technologies, Inc. Reports Third Quarter 2018 Financial Results NEWTOWN, Pa., November 8, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today re
Read more →HSDTEx. 99.1 Helius Medical Technologies Receives Medical Device License Clearance from Health Canada for PoNS Device NEWTOWN, PA.
Helius Medical Technologies Receives Medical Device License Clearance from Health Canada for PoNS Device NEWTOWN, PA., October 22, 2018 - (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neu
Read more →HSDTHelius Medical Technologies Submits Request for FDA 510(k) Clearance of the PoNS Device NEWTOWN, PA.
Helius Medical Technologies Submits Request for FDA 510(k) Clearance of the PoNS Device NEWTOWN, PA., September 4, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellnes
Read more →HSDTHelius Medical Technologies, Inc. Names Jennifer Laux as Chief Commercialization Officer NEWTOWN, Pa.
Helius Medical Technologies, Inc. Names Jennifer Laux as Chief Commercialization Officer NEWTOWN, Pa., July 12, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, i
Read more →HSDTHELIUS MEDICAL TECHNOLOGIES, INC. ANNOUNCES UPLISTING TO NASDAQ AND PRICING OF PUBLIC OFFERING OF CLASS A
HELIUS MEDICAL TECHNOLOGIES, INC. ANNOUNCES UPLISTING TO NASDAQ AND PRICING OF PUBLIC OFFERING OF CLASS A COMMON STOCK AND WARRANTS April 11, 2018 Newtown, PA Helius Medical Technologies, Inc. (TSX: HSM, NASDAQ: HSDT) ( Helius or the Company ) today announced the pricing of a
Read more →HSDTand other factors, many of which are beyond the control of the Company, including the Company's ability to satisfy quantitative and qualitative initial listing standards of a national securities exchange prior to the abi
Helius Medical Technologies Completes Reverse Split of its Class A Common Stock (Newtown, PA) - January 23, 2018 - Helius Medical Technologies, Inc. (TSX: HSM) (TXS:HSM.WT) (OTCQB: HSDT) ("Helius" or the "Company"), a medical technology company focused on neurological wellness,
Read more →HSDTHelius Medical Technologies Selects Key Tronic Corporation as its Commercial Contract Manufacturing Partner NEWTOWN, PA
Helius Medical Technologies Selects Key Tronic Corporation as its Commercial Contract Manufacturing Partner NEWTOWN, PA - January 5, 2018 - Helius Medical Technologies, Inc. (TSX: HSM and HSM.WT and OTCQB: HSDT) ("Helius" or the "Company"), a medical technology company focused o
Read more →HSDTHELIUS CONTACTS: Investor Relations: Josh Berg, 415-205-7891 info@heliusmedical.com
Helius Medical Technologies Announces Planned Five-for-One Reverse Stock Split NEWTOWN, PA - January 3, 2018 - Helius Medical Technologies, Inc. (TSX: HSM and HSM.WT and OTCQB: HSDT) ("Helius" or the "Company"), a medical technology company focused on neurological wellness, anno
Read more →HSDTHelius Medical Technologies Announces Closing of Second Tranche of Private Placement NEWTOWN, PA
Helius Medical Technologies Announces Closing of Second Tranche of Private Placement NEWTOWN, PA - December 28, 2017 - Helius Medical Technologies, Inc. (TSX: HSM and HSM.WT and OTCQB: HSDT) ("Helius" or the "Company"), a medical technology company focused on neurological wellne
Read more →HSDTHelius Medical Technologies Announces Closing of First Tranche of Private Placement NEWTOWN, PA
Helius Medical Technologies Announces Closing of First Tranche of Private Placement NEWTOWN, PA - December 22, 2017 - Helius Medical Technologies, Inc. (TSX: HSM and HSM.WT and OTCQB: HSDT) ("Helius" or the "Company"), a medical technology company focused on neurological wellnes
Read more →HSDThsdt-ex991_6.pptx.htm A Revolution in Mind
A Revolution in Mind November 9, 2017 www.heliusmedical.com | TSE:HSM | OTCQB:HSDT Legal Disclaimers This presentation includes certain statements that may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
Read more →HSDTFact Sheet
Fact Sheet: July 10, 2017 Developer of the Portable Neuromodulation Stimulator (PoNS ) Therapy Helius Medical Technologies is a Newtown, PA-based medical device company developing and commercializing the PoNS Therapy platform, a powerful wearable direct current stimulation tec
Read more →HSDTHelius Medical Announces Closing of CAD$7.0 Million Private Placement NEWTOWN, PA
Helius Medical Announces Closing of CAD$7.0 Million June 27, 2017 Helius Medical Technologies, Inc. (TSX: HSM and HSM.WT and OTCQB: HSDT) ( Helius or the Company ), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, is pl
Read more →HSDTHelius Medical Technologies A Revolution in Mind May 2017 Helius MEDICAL TECHNOLOGIES www.heliusmedical.com | TSX: HSM | OTCQB: HSDT Legal Disclaimers This presentation contains forward-looking statements and forward-loo
Helius Medical Technologies A Revolution in Mind Helius MEDICAL TECHNOLOGIES www.heliusmedical.com | TSX: HSM | OTCQB: HSDT presentation contains forward-looking statements and forward-looking information as such terms are defined under applicable U.S. federal securities and
Read more →HSDTHELIUS MEDICAL TECHNOLOGIES INC. ANNOUNCES CAD$10.8 MILLION PUBLIC OFFERING OF CLASS A
HELIUS MEDICAL TECHNOLOGIES INC. ANNOUNCES CAD$10.8 MILLION PUBLIC OFFERING OF CLASS A COMMON STOCK February 9, 2017 Newtown, PA Helius Medical Technologies, Inc. (TSX: HSM, OTCQB: HSDT) ( Helius or the Company ) is pleased to announce that, in connection with the proposed pub
Read more →HSDTHELIUS MEDICAL TECHNOLOGIES, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF CLASS A
HELIUS MEDICAL TECHNOLOGIES, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF CLASS A COMMON STOCK February 8, 2017 Newtown, PA Helius Medical Technologies, Inc. (TSX: HSM, OTCQB: HSDT) ( Helius or the Company ) announced today that it intends to offer and sell, subject to market co
Read more →HSDTRESIGNATION OF DIRECTOR TO: Helius Medical Technologies, Inc. (the " Company ") I hereby resign as a director of the Company. I confirm that there is no compensation or other indebtedness owing to me, and that I have no
RESIGNATION OF DIRECTOR TO: Helius Medical Technologies, Inc. I hereby resign as a director of the Company. I confirm that there is no compensation or other indebtedness owing to me, and that I have no claims against the Company. DATED: January 30, 2017
Read more →HSDTFiled by newsfilecorp.com HELIUS MEDICAL TECHNOLOGIES AND U.S. ARMY EXTEND SOLE SOURCE CONTRACT FOR THE PONS DEVICE TESTING AND DEVELOPMENT (Newtown, PA)
HELIUS MEDICAL TECHNOLOGIES AND U.S. ARMY EXTEND SOLE SOURCE FOR THE PONS DEVICE TESTING AND DEVELOPMENT (Newtown, PA) November 21, 2016 - Helius Medical Technologies, Inc. (TSX: HSM) (OTCQB: HSDT) ( Helius or the Company ) announced that NeuroHabilitation Corporation ( NHC )
Read more →HSDTFocused on the treatment of neurological symptoms caused by disease or trauma" Helius Medical Technologies Appoints Thomas Griffin to Board of Directors and Chairman of the Audit Committee. Newtown, PA
Helius Medical Technologies Appoints Thomas Griffin to Board of Directors and Chairman of the Audit Committee. Newtown, PA - August 8, 2016 - Helius Medical Technologies, Inc. (TSX: HSM, OTCQB: HSDT) ("Helius" or the "Company") a company focused on the treatment of neurological
Read more →HSDTFiled by newsfilecorp.com Helius Medical Announces Proceeds of $1.4 Million from Exercise of Warrants
Helius Medical Announces Proceeds of $1.4 Million from Exercise of Warrants THIS NEWS RELEASE IS INTENDED FOR IMMEDIATE RELEASE NEWTOWN, PA June 6, 2016 Helius Medical Technologies, Inc. (TSX: HSM, and OTCQB: HSDT) ("Helius" or the "Company") a medical technology company foc
Read more →HSDTFiled by newsfilecorp.com Helius Medical Technologies Restates and Re-files Historical Financial Statements for Non-Cash Reclassification of Warrants NEWTOWN, PA
Helius Medical Technologies Restates and Historical Financial Statements for Non-Cash Reclassification NEWTOWN, PA April 26, 2016 Helius Medical Technologies, Inc. (TSX: HSM and OTCQB: HSDT) ("Helius" or the "Company") The Company is issuing the following press release to cla
Read more →HSDTFiled by newsfilecorp.com HELIUS MEDICAL TECHNOLOGIES ANNOUNCES ALLOWANCES OF 10 NEW PATENTS (Newtown, PA)
HELIUS MEDICAL TECHNOLOGIES ANNOUNCES ALLOWANCES OF 10 NEW (Newtown, PA) - January 4, 2016 - Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius", or the "Company"), a medical technology company focused on the treatment of neurological symptoms caused by disea
Read more →HSDTFiled by newsfilecorp.com HELIUS MEDICAL TECHNOLOGIES ANNOUNCES RECEIPT OF REMAINDER OF A&B FUNDING, CHANGES TO BOARD OF DIRECTORS, AND EXTENSION OF CRADA AGREEMENT THROUGH DECEMBER 2017 (Newtown PA)
HELIUS MEDICAL TECHNOLOGIES ANNOUNCES RECEIPT OF REMAINDER OF A&B FUNDING, CHANGES TO BOARD OF DIRECTORS, AND EXTENSION OF CRADA AGREEMENT THROUGH DECEMBER 2017 (Newtown PA) December 31, 2015 - Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ( Helius , or the Compan
Read more →HSDTFiled by newsfilecorp.com HELIUS MEDICAL TECHNOLOGIES NAMES JOYCE LAVISCOUNT AS CFO/COO Newtown PA, October 21 2015 - Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius" or the "Company"), a company focus
HELIUS MEDICAL TECHNOLOGIES NAMES JOYCE LAVISCOUNT AS CFO/COO Newtown PA, October 21 2015 - Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius" or the "Company"), a company focused on the treatment of neurological symptoms caused by disease or trauma, has appoint
Read more →HSDTFiled by newsfilecorp.com Helius Medical Technologies Inc. and A&B Company Limited Enter Into Strategic Agreement For The Development of PoNS TM Therapy in China, Hong Kong, Macao, Taiwan and Singapore. A&B HK) Ltd Provi
Helius Medical Technologies Inc. and A&B Company Limited Enter Into Strategic Agreement For The Development of PoNSTM Therapy in China, Hong Kong, Macao, Taiwan and A&B HK) Ltd Provides US $7.0M Funding Commitment to Helius Medical Technologies Inc. Newtown PA, and HONG KONG
Read more →HSDTHELIUS MEDICAL TECHNOLOGIES INVENTORS GRANTED US PATENT NO. 9,072,889, "Systems for Providing Non-Invasive Neurorehabilitation of a Patient NEWTOWN, PA
HELIUS MEDICAL TECHNOLOGIES INVENTORS GRANTED US PATENT NO. for Providing Non-Invasive Neurorehabilitation of NEWTOWN, PA July 15, 2015 - Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ( Helius , or the Company ) announced today that the US Patent and Trademark Off
Read more →HSDTHelius Medical Technologies Announces Clinical Device Readiness for PoNS 4.0 Newtown, PA June 25 2015 - Helius Medical Technologies, Inc. (CSE: HSM) (OTCQB: HSDT) ( Helius ) is pleased to announce that it has successfull
Helius Medical Technologies Announces Clinical Device Readiness for PoNS 4.0 Newtown, PA June 25 2015 - Helius Medical Technologies, Inc. (CSE: HSM) (OTCQB: HSDT) ( Helius ) is pleased to announce that it has successfully released the first clinical version of the Portable Ne
Read more →Competitive Position
How HSDT ranks across every disease it competes inCompetitive Position is a premium feature
See how HSDT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial